Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
79 hedge funds and large institutions have $69.1M invested in Unity Biotechnology in 2020 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 24 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 23
1.29% less ownership
Funds ownership: 5.07% → 3.78% (-1.3%)
6% less funds holding
Funds holding: 84 → 79 (-5)
21% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 24
35% less call options, than puts
Call options by funds: $462K | Put options by funds: $706K
68% less capital invested
Capital invested by funds: $216M → $69.1M (-$147M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.87M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.05M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$569K |
| 4 |
LPL Financial
San Diego,
California
|
+$406K |
| 5 |
SO
STRS Ohio
Columbus,
Ohio
|
+$384K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$15.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.89M |
| 3 |
IFA
Invus Financial Advisors
New York
|
-$6.93M |
| 4 |
Millennium Management
New York
|
-$4.62M |
| 5 |
Renaissance Technologies
New York
|
-$2.44M |
UBX Hedge Fund Activity: Q3 2020 in Review
79 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q3 2020, worth a combined $69.1M — down 68% from $216M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of UBX and 19 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 22 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $1.87M. The largest seller was Capital World Investors, exiting entirely with an estimated $15.9M sold.
- 79 institutional investors held Unity Biotechnology (UBX) as of Q3 2020, down from 84 in Q2 2020.
- Funds reported $69.1M of Unity Biotechnology stock for Q3 2020, down 68% quarter-over-quarter.
- 19 funds opened new Unity Biotechnology positions in Q3 2020 and 24 closed out, a net change of -5 holders.
- The largest Unity Biotechnology buyer in Q3 2020 was EcoR1 Capital, an estimated $1.87M added.
- The largest Unity Biotechnology seller in Q3 2020 was Capital World Investors, an estimated $15.9M sold.
Based on aggregated 13F filings for Q3 2020.